TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02494544

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Off the Shelf Total Knee Replacement
Description: A knee replacement system by DePuy, Zimmer, Biomet, Smith \& Nephew, or Stryker

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Off the Shelf Total Knee Replacement
Description: A knee replacement system by DePuy, Zimmer, Biomet, Smith \& Nephew, or Stryker
Study: NCT00281658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel infusion
Description: Paclitaxel 80 mg/m2 every 3 weeks, 4th week rest for minimum 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel infusion
Description: Paclitaxel 80 mg/m2 every 3 weeks, 4th week rest for minimum 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Paclitaxel Matching Placebo
Study: NCT02975362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture Treatment
Description: Acupuncture Treatment Acupoint selection base on disease stage combined adjunct acupuncture acupoint base on syndrome differentiation.①Base on disease stage: Flaccid paralysis period: DU24, DU20, Motor Area , LI15, LI14, LI11, SJ5, LI4, GB31, EX-LE2, GB34, ST36, ST40.Spastic period: DU24, DU20, Motor Area , SJ10, SJ13, LI10, SJ8, SJ5, SJ4, SJ4, BL37, BL40, BL39, BL55, BL57, ST41, GB40, BL60.②Base on syndrome differentiation:Excess syndrome of yang-type: LR3, ST37; Deficiency syndrome of Yang-type: KI3, BL23; Excess syndrome of yin-type: SP9, GB20;Deficiency syndrome of Yin-type: CV6, BL23.③Electroacupuncture acupoint: Flaccid paralysis period: LI15, LI4, GB31, ST40; Spastic period: SJ13, SJ5, BL40, BL57.30minutes each time,twenty times / treatment course，two treatment courses in total.
Study: NCT02494544

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ConforMIS iTotal Knee Replacement
Description: A knee replacement performed with patient specific implant and surgical jigs.
Study: NCT03365297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: 240mg (4x60mg) oral tablets daily over a max. of 90 days
Study: NCT02008305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: protocol of optimization ALARA
Study: NCT02975362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation Treatment
Description: Rehabilitation treatment The rehabilitation program was designed according to the Chinese stroke rehabilitation treatment guidelines, which included physical therapy (PT) and occupational therapy (OT). The rehabilitation programs will be carried out five times a week (that is, Monday to Friday) for 8 weeks, and every time the rehabilitation treatment( PT and OT) will last approximately for 1 hour. All rehabilitation treatment will be carried out by qualified therapists
Study: NCT02008305

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: protocol of optimization Philips
Study: NCT03117257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Description: Device: Chrono-chemotherapy Drug: induction Chrono-chemotherapy Drug: Lobaplatin chrono-chemotherapy Radiation: intensity-modulated radiation therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Device: Chrono-chemotherapy Drug: induction Chrono-chemotherapy Drug: cisplatin chrono-chemotherapy Radiation: intensity-modulated radiation therapy
Study: NCT04441216

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rhizoma Coptidis, Radix Astragali and Flos Lonicerae
Description: granule

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rhizoma Coptidis, Radix Astragali and Flos Lonicerae, Ophiopogonis Radix
Description: granule

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rhizoma Coptidis, Radix Astragali and Flos Lonicerae, Ophiopogonis Radix
Description: granule
Study: NCT01606540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tablets Ibumetin and placebo
Description: Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after reposition.~Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after reposition. The following days placebo tablets.~Group C: Placebo tablets 1 week after reposition.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tablets Ibumetin and placebo
Description: Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after surgery.~Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after surgery. The following days placebo tablets.~Group C: Placebo tablets for 1 week after surgery.
Study: NCT02479893

Intervention type: PROCEDURE
Intervention: polypectomy
Description: Polyps size up to 0.8 cm will removed from the left colon.Re examination in 6 months period with biopsy from the scar of polypectomy.

Intervention type: PROCEDURE
Intervention: polypectomy
Description: Polyps size up to 0.8 cm will removed from the left colon.Re examination in 6 months period with biopsy from the scar of polypectomy.

Intervention type: PROCEDURE
Intervention: polypectomy
Description: Polyps size up to 0.8 cm will removed from the left colon.Re examination in 6 months period with biopsy from the scar of polypectomy.
Study: NCT01520909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Thrombopoietin receptor agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Thrombopoietin receptor agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with no active pharmaceutical ingredient
Study: NCT06275061

Intervention type: PROCEDURE
Intervention: Metabolic and Bariatric Surgery
Description: Metabolic and bariatric surgery is weight loss surgery that results in weight loss and resolution of metabolic disorders.
Study: NCT04517162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Collagen-Polyvinylpyrrolidone
Description: 1.5 mL of polymerized-type I collagen or placebo, every 12 h for 3 days and then every 24 h for 4 days (in total 10 injections in 7 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Collagen-Polyvinylpyrrolidone
Description: 1.5 mL of polymerized-type I collagen or placebo, every 12 h for 3 days and then every 24 h for 4 days (in total 10 injections in 7 days)
Study: NCT01998217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Patients in Rem group receive sedation and analgesia with remifentanil, dose of which will be determined by the up-and-down method.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen and remifentanil
Description: Patients in this group receive sedation and analgesia with flurbiprofen and remifentanil, dose of which was determined by the up-and-down method.
Study: NCT00091260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: dexamethasone 20 mg daily (10 mg BID) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone
Study: NCT03153930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking breaks
Description: In-Lab (full sample): participants will be asked to walk on a treadmill for 3 minutes every 30 minutes at a moderate pace during a 3-hour OGTT Free-living (sub-sample; N=12): participants will be prompted via an ActivPAL vtap monitor to walk for 3 minutes every time sedentary behavior lasts longer than 30 continuous minutes

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sitting only
Description: In-Lab (full sample): participants will remain seated for 3 hours during an OGTT Free-living (sub-sample; N=12): participants will perform their habitual sedentary behaviors
Study: NCT04513730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: A device originally designed with the function of keeping the user in a comfortable position of pelvic suspension, in dorsal decubitus, with fixation in the popliteal region and ankles was built to promote lumbar traction. The device is designed in autoCAD software with 2d technical representations and 3d electronic model. It consists of a structure of pipes and fittings and padded material at the support points.
Study: NCT03341585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: expiration lente prolongée
Description: l'Expiration Lente Prolongée (ELPr) is a passive technique to enhance the expiration used in infants, obtained by a slow and increasing manual thoraco-abdominal pression applied at the end of a spontaneous expiration till the residual volume. The aim is to obtain a bigger expired volume compared to a normal expiration and drain the mucus out of the airways (Postiaux 2003). This technique has been invented by Guy Postiaux and is used in the Chest Physiotherapy (CPT).
Study: NCT03227198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramyocardial injection of stem cell
Description: Autologous bone marrow-derived mononuclear cells are obtained from 100-150ml of bone marrow aspirated under local anaesthesia from the iliac crest. Intramyocardial injection of the cells is performed in patients with Heart failure in open heart surgery (CABG)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of Placebo in patients with Heart failure in open heart surgery (CABG)
Study: NCT01467765

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Elental
Description: 200Kcal/200mL of liquid nutrient for 15 min at 7:30 am is administered in PEG patients

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Elental
Description: 200Kcal/200mL of liquid nutrient for 15 min at 7:30 am is administered in PEG patients
Study: NCT01371786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciclesonide nasal aerosol
Description: A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone Aqueous (AQ) nasal spray
Description: A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle
Study: NCT01916317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% lignocaine 60mM
Study: NCT00624065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carvedilol controlled release/lisinopril
Description: carvedilol CR + lisinopril given as separate pills

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisinopril + placebo
Description: lisinopril plus placebo to match carvedilol CR
Study: NCT04038801

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadrant-wise scaling and root planning (Q-SRP)
Description: Quadrant-wise scaling and root planing were performed by assortment of manuel periodontal curettes over four visits at 1-weekly intervals.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full-mouth ultrasonic debridement (FMUD)
Description: Subgingival debridement were performed by a piezoceramic ultrasonic inserts in two visits of the same day.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full-mouth disinfection (FMD)
Description: Subgingival debridement were performed by a piezoceramic ultrasonic inserts and an intensive regime of chlorhexidine in two visits of the same day.
Study: NCT02171793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01845662

Intervention type: OTHER
Intervention: Surgical or non-surgical management
Description: Retrospective surgical (splenectomy) or non-surgical management (embolization or conservative management)
Study: NCT03185039

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood and tumor samples
Description: Blood and tumor samples
Study: NCT02779894

Intervention type: OTHER
Group type: OTHER
Intervention: Remote control of patients
Description: Diagnosis outside the hospital (3 Home PR) CPAP (if needed) titration at home REmote control of patient's during 3 months by video or phonoconference
Study: NCT03702894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clavamox
Description: Clavamox, Film-coated Tablets, 875 mg + 125 mg, manufactured by Pharmtechnology LLC, Belarus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmentin®
Description: Augmentin®, Film-coated Tablets, 875 mg + 125 mg, marketed by GlaxoSmithKline Trading CJSC, Russia
Study: NCT00374335

Intervention type: PROCEDURE
Group type: OTHER
Intervention: abdominal ultrasound
Description: abdominal ultrasound to detect hepatic hemangiomas

Intervention type: OTHER
Group type: OTHER
Intervention: Dermatologic Examination
Description: Complete dermatologic examination
Study: NCT01019889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCRT
Description: 4 capsules,three times daily, for 7days or within symptom disappearance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPS
Description: 4 capsules, three times daily, for 7days or within symptom disappearance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 4 capsules, three times daily, for 7days or within symptom disappearance
Study: NCT02724462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-delivered Intervention (SmartQuit)
Description: The experimental arm includes an intervention using a novel smartphone smoking cessation app.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: : Smartphone-delivered Intervention (Standard of care app)
Description: The control intervention uses a standard of care smartphone smoking cessation app.
Study: NCT03861845

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard off-the-shelf pillbox
Description: Then the participant will receive a store bought one-dose per day pillbox.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom off-the-shelf pillbox
Description: Then the participant will be administered an off-the-shelf pillbox that was purchased specifically for the participant's preferences, routine, medication regimen, and skills/abilities.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom designed and manufactured pillbox
Description: Then the participant will describe any design preferences for the pillbox. The researcher will design and manufacture the pillbox using a 3D printer, publically available 3D printing object repository, and computer aided design software.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education & Training
Description: The participant will receive education and training on how to use the pillbox and how to incorporate the pillbox and taking medications into their daily routine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education & Training
Description: The participant will receive education and training on how to use the pillbox and how to incorporate the pillbox and taking medications into their daily routine.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education & Training
Description: The participant will receive education and training on how to use the pillbox and how to incorporate the pillbox and taking medications into their daily routine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflection on medication routines
Description: The participant will reflect on his or her daily routine, medication regimen, and use of existing pillboxes. The participant will also engage in a hands-on standardized pillbox task.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflection on medication routines
Description: The participant will reflect on his or her daily routine, medication regimen, and use of existing pillboxes. The participant will also engage in a hands-on standardized pillbox task.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reflection on medication routines
Description: The participant will reflect on his or her daily routine, medication regimen, and use of existing pillboxes. The participant will also engage in a hands-on standardized pillbox task.
Study: NCT01061866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3-phthalimidoglutarimide (Thalidomide)
Description: Thalidomide at 200 mg dosage bid was administered during a twelve month period.
Study: NCT01623726

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Transcranial Direct Current Stimulation. Daily sessions with a total of 10 days intervention. Each intervention will take place with a 2mA intensity during 20 minutes. The current will be delivered by Chattanooga Iontophoresis Dual Channel Delivery Device, that stands for a 2-channels tDCS device in which previous dosage can be set as default to maintain frequently used treatment parameters. Main features include (a) Beeping alerts if electrode fault for open current or high impedance, low battery, treatment completion or power left on; (b)automatic 30 second current ramp up and down during power on/off keeps patient comfortable; (c) Current can be set in 0.1 mA increments between 0.5 mA and 4 mA.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Transcranial Direct Current Stimulation. Daily sessions with a total of 10 days intervention. Each intervention will take place with a 2mA intensity during 20 minutes. The current will be delivered by Chattanooga Iontophoresis Dual Channel Delivery Device, that stands for a 2-channels tDCS device in which previous dosage can be set as default to maintain frequently used treatment parameters. Main features include (a) Beeping alerts if electrode fault for open current or high impedance, low battery, treatment completion or power left on; (b)automatic 30 second current ramp up and down during power on/off keeps patient comfortable; (c) Current can be set in 0.1 mA increments between 0.5 mA and 4 mA.
Study: NCT01678066

Intervention type: DEVICE
Intervention: Bilateral cardiac output
Study: NCT00003472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Adults with a recurrent/progressive Oligodendroglioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT04988191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Neoadjuvant therapy: Toripalimab is given by intravenous infusion at 3mg/kg d1 every 2 weeks for 3 cycles.~Adjuvant therapy: Toripalimab is given by intravenous infusion at a dose of 240mg every 3 weeks for up to 9 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Neoadjuvant therapy: Bevacizumab is given by intravenous infusion at 5mg/kg d1 every 2 weeks for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Neoadjuvant therapy: Irinotecan is given by intravenous infusion at 180mg/m2 d1 every 2 weeks for 2 cycles.
Study: NCT04605991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC
Study: NCT00877344

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate insertion
Description: Immediate timing of insertion for a LNG-IUC OR Copper 380mg T-shaped IUD after an abortion for a gestational age between 12 weeks zero days and 23 weeks 6 days. Immediate insertions occur during the visit for the abortion immediately after the abortion is complete, interval insertions will be scheduled for not earlier than two weeks and not later than four weeks after the abortion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interval insertion
Description: Interval Timing of insertion for a LNG-IUC OR Copper 380mg T-shaped IUD after an abortion for a gestational age between 12 weeks zero days and 23 weeks 6 days. Immediate insertions occur during the visit for the abortion immediately after the abortion is complete, interval insertions will be scheduled for not earlier than two weeks and not later than four weeks after the abortion.
Study: NCT04605991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Administered SC
Study: NCT00775047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist-administered
Description: women will receive their injections at a pharmacy by a clinical pharmacist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clinic-administered injections
Description: women will return for their injections to the clinic where recruitment took place. They will receive one at 3 months and 6 months.
Study: NCT03322319

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue biopsies
Description: It is commonly accepted that the diagnosis of cardiac amyloidosis may be based on presence of characteristic cardiac abnormalities in echography, associated with the detection of bi-refractive appearance deposits in polarized light after congo red staining of a biopsy fragment.~Usually a biopsy of the abdominal fat or salivary glands can suffice. More rarely, in case of persistent doubt (eg negativity of congo red despite a characteristic appearance, which may occur in 20 to 30% of cases), it will be necessary to perform an endomyocardial biopsy (EMB).
Study: NCT03554694

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotics
Description: Galactooligosaccharides (GOS) (prebiotics) will be consumed by the participants for 4-6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maltodextrin (placebo)
Description: Maltodextrin (placebo) will be consumed by the participants for 4-6 weeks
Study: NCT02171910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxapram

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An injection and infusion of normal saline (NaCl 0.9%) as a placebo comparator to doxapram
Study: NCT04211129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Patients receiving sham acupuncture and sham mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. Same Hwato acupuncture device was used to blind the subjects, but do not puncturing into the skin and do not have the deqi sensation. The surface temperature of acupoints was maintained at 37℃± 1℃ for moxibustion.
Study: NCT02770157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-3002

Intervention type: DRUG
Group type: OTHER
Intervention: DA-3002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotropin®